Indeed, based on this rationale, several randomized controlled trials are evaluating the effectiveness of ICBs targeting PD-(L)1 and CTLA-4 on HCC recurrence after curative treatments [24,25]. Here, CD274 is linked to hepatocellular carcinoma.